Levin Capital Strategies L.P. Buys 467,647 Shares of ARS Pharmaceuticals, Inc. $SPRY

Levin Capital Strategies L.P. lifted its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 157.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 764,294 shares of the company’s stock after acquiring an additional 467,647 shares during the period. Levin Capital Strategies L.P.’s holdings in ARS Pharmaceuticals were worth $7,681,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. CenterBook Partners LP bought a new position in shares of ARS Pharmaceuticals during the 3rd quarter valued at about $5,149,000. Vanguard Group Inc. raised its stake in shares of ARS Pharmaceuticals by 7.3% during the third quarter. Vanguard Group Inc. now owns 3,500,303 shares of the company’s stock worth $35,178,000 after acquiring an additional 237,630 shares in the last quarter. Aberdeen Group plc lifted its holdings in shares of ARS Pharmaceuticals by 106.1% in the 3rd quarter. Aberdeen Group plc now owns 3,097,022 shares of the company’s stock worth $31,125,000 after acquiring an additional 1,594,447 shares during the last quarter. Profund Advisors LLC boosted its stake in shares of ARS Pharmaceuticals by 54.1% in the 3rd quarter. Profund Advisors LLC now owns 26,330 shares of the company’s stock valued at $265,000 after purchasing an additional 9,242 shares in the last quarter. Finally, American Assets Inc. bought a new position in shares of ARS Pharmaceuticals during the 3rd quarter valued at $553,000. Institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research downgraded ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 27th. Finally, Roth Mkm initiated coverage on shares of ARS Pharmaceuticals in a report on Tuesday, November 4th. They issued a “buy” rating and a $30.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $30.67.

ARS Pharmaceuticals Trading Up 0.7%

Shares of SPRY opened at $9.45 on Thursday. ARS Pharmaceuticals, Inc. has a 1-year low of $6.66 and a 1-year high of $18.90. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. The firm’s 50-day moving average price is $10.59 and its 200-day moving average price is $10.72. The firm has a market capitalization of $934.13 million, a price-to-earnings ratio of -11.67 and a beta of 0.79.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.